Geron Corporation (GERN) Analysts See $0.40 EPS

October 14, 2018 - By Hazel Jackson

Geron Corporation (NASDAQ:GERN) LogoInvestors sentiment increased to 1.77 in 2018 Q2. Its up 0.58, from 1.19 in 2018Q1. It improved, as 14 investors sold Geron Corporation shares while 21 reduced holdings. 24 funds opened positions while 38 raised stakes. 67.30 million shares or 14.69% more from 58.68 million shares in 2018Q1 were reported.
123,131 are held by National Bank & Trust Of Montreal Can. State Street Corp has invested 0% in Geron Corporation (NASDAQ:GERN). 12,407 are held by Zeke Advsr Lc. Us State Bank De reported 24,225 shares stake. Credit Suisse Ag has 140,656 shares for 0% of their portfolio. Ameritas Inv Partners Inc owns 13,270 shares for 0% of their portfolio. Metropolitan Life Ins New York holds 50,480 shares. Element Mgmt Limited Liability stated it has 0% of its portfolio in Geron Corporation (NASDAQ:GERN). 12,150 were accumulated by Royal Bank Of Canada. Moreover, California State Teachers Retirement System has 0% invested in Geron Corporation (NASDAQ:GERN) for 243,680 shares. Northwestern Mutual Wealth Mgmt holds 0% in Geron Corporation (NASDAQ:GERN) or 2,000 shares. Goldman Sachs Group has invested 0% in Geron Corporation (NASDAQ:GERN). The Pennsylvania-based Glenmede Tru Na has invested 0% in Geron Corporation (NASDAQ:GERN). M Securities Inc owns 25,000 shares or 0.02% of their US portfolio. Quantitative Invest Ltd Liability Co holds 0.02% in Geron Corporation (NASDAQ:GERN) or 272,000 shares.

Since August 24, 2018, it had 0 insider buys, and 2 insider sales for $7.34 million activity. 1.36M Geron Corporation (NASDAQ:GERN) shares with value of $6.14 million were sold by ROSENFIELD STEPHEN.

Analysts expect Geron Corporation (NASDAQ:GERN) to report $0.40 EPS on November, 7.They anticipate $0.44 EPS change or 1,100.00 % from last quarter’s $-0.04 EPS. GERN’s profit would be $73.45M giving it 1.06 P/E if the $0.40 EPS is correct. After having $-0.04 EPS previously, Geron Corporation’s analysts see -1,100.00 % EPS growth. The stock increased 1.81% or $0.03 during the last trading session, reaching $1.69. About 3.49M shares traded. Geron Corporation (NASDAQ:GERN) has risen 181.60% since October 14, 2017 and is uptrending. It has outperformed by 165.98% the S&P500.

Geron Corporation operates as a biopharmaceutical company. The company has market cap of $310.32 million. The firm supports the clinical stage development of a telomerase inhibitor, imetelstat, for treating hematologic myeloid malignancies. It currently has negative earnings. It has collaboration and license agreement with Janssen Biotech, Inc. to develop and commercialize imetelstat worldwide for indications in oncology, including hematologic myeloid malignancies and other human therapeutic uses.

More notable recent Geron Corporation (NASDAQ:GERN) news were published by: Seekingalpha.com which released: “Geron: The Last Chapter” on September 21, 2018, also Seekingalpha.com with their article: “Geron: Interesting Times” published on October 02, 2018, Globenewswire.com published: “Geron Announces Discontinuation of Imetelstat Collaboration by Janssen” on September 27, 2018. More interesting news about Geron Corporation (NASDAQ:GERN) were released by: Seekingalpha.com and their article: “Geron: How To Play The Imetelstat Catalyst” published on September 26, 2018 as well as Fool.com‘s news article titled: “Why Geron Corporation’s Stock Is Sinking, Again” with publication date: September 28, 2018.

Geron Corporation (NASDAQ:GERN) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>